NEWS COMMENTARY

Digital therapeutic Proteus files for bankruptcy

Published:
June 17, 2020
Coverage:
Digital Transformation More...
Activities:
Bankruptcy
Very important

This has been a long time coming, largely precipitated by problematic partnerships that undermined the entire value proposition of Proteus. The company is now seeking a buyer for its technology – and clients who are interested in engaging with medication adherence should consider snapping up this technology. Medication adherence is a significant challenge across a number of healthcare verticals, including substance abuse, sexual health, chronic disease, and cancer care. Clients will need to avoid the mistakes of the Otsuka partnership, but this is an opportunity to capitalize on a problem estimated to be worth between $100 billion and $289 billion per year for the healthcare industry.

For the original news article, click here .


Further Reading

Digital Therapeutics

State of the Market Report | March 30, 2020

Digital therapeutics are a key element of the ongoing digital transformation of healthcare. These tools support personalized yet scalable health services, which is critical where high costs and accessibility represent barriers to quality healthcare. This report will outline the landscape of digital... Not part of subscription

Emerging go-to-market strategies overcome regulatory and reimbursement hurdles to tap into the $4 trillion health and wellness market

Analyst Insight | December 02, 2020

Currently, the most common approach to a new healthcare solution is building it with a particular set of insurance reimbursement codes in mind (see this insight), getting clinical validation as part of the regulatory approval process, and deploying to the market with a reimbursement plan already in ... Not part of subscription

Recovering COVID-19 patients may face higher risk of developing blood clots

News Commentary | April 14, 2021

Scientists at Singapore's Nanyang Technological University reported that recovering COVID‑19 patients with preexisting cardiovascular conditions may be at a higher risk of developing blood clots. The findings come at a time when vaccines from AstraZeneca and Johnson & Johnson have reported rare ... Not part of subscription